Patents by Inventor Juliet GRAY

Juliet GRAY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY
    Publication number: 20230058227
    Abstract: Described is the sequential administration of first a Treg depleting antibody mole-cute selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. De-scribed are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
    Type: Application
    Filed: August 11, 2022
    Publication date: February 23, 2023
    Inventors: Björn FRENDÉUS, Linda MÅRTENSSON, Monika SEMMRICH, Ingrid TEIGE, Stephen BEERS, Aymen AL-SHAMKHANI, Juliet GRAY, Martin GLENNIE
  • Combination of a Treg depleting anti-4-1BB antibody and anti-PD1 antibody
    Patent number: 11447549
    Abstract: Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: September 20, 2022
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Björn Frendéus, Linda Mårtensson, Monika Semmrich, Ingrid Teige, Stephen Beers, Aymen Al-Shamkhani, Juliet Gray, Martin Glennie
  • NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY
    Publication number: 20200207855
    Abstract: Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 2, 2020
    Inventors: Björn FRENDÉUS, Linda MÅRTENSSON, Monika SEMMRICH, Ingrid TEIGE, Stephen BEERS, Aymen AL-SHAMKHANI, Juliet GRAY, Martin GLENNIE